Biocon Biologics and Viatris Receive CHMP's Positive Opinion for Abevmy (biosimilar- bevacizumab)
Shots:
- The CHMP has adopted a positive opinion recommending the marketing authorization of Abevmy (inj. bevacizumab 100 & 400mg)- which is co-developed by Biocon and Viatris
- The companies expect the EC’s decision in May’2021- which will grant the approval in 27 EU member countries and EEA member states of Norway- Iceland and Liechtenstein. For the UK- MHRA’s reliance procedure” will be followed- and the UK marketing authorization can be expected shortly after the EC decision
- Abevmy is a biosimilar referencing Roche’s Avastin and is a humanized mAb that selectively binds to human VEGF and neutralizes its biological activity. Abevmy is available for all indications of its reference products
Ref: Biocon Biologics | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com